Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079622 | 0.95 | PTGER4 (0.37) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10078914 | 0.93 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10079272 | 0.91 | PTGER4 (0.40) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL1590083 | 0.84 | PTGER4 (0.53) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10078417 | 0.83 | PTGER4 (0.43) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10078896 | 0.83 | PTGER4 (0.40) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL13459021 | 0.82 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10078909 | 0.82 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL10058504 | 0.80 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL1590079 | 0.80 | PTGER4 (0.52) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRK1, OPRD1, OPRL1 | PTGER4 106/4885CYP1A2 41/4885CYP2D6 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.